Evidence map›Paper›PMID 26989717›Full record

ArticleReports of biochemistry & molecular biology2013

Construction and eukaryotic expression of recombinant large hepatitis delta antigen.

Behnaz Forouhar Kalkhoran, Farida Behzadian, Farzaneh Sabahi, Mohsen Karimi, Hesam Mirshahabi

Open access · greenAbstract read
In one paragraph

Article in Reports of biochemistry & molecular biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Behnaz Forouhar KalkhoranDepartment of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Farida BehzadianDepartment of Molecular Genetics, Research Center for Sciences and Biotechnology, Malek Ashtar University, Tehran, Iran.
Farzaneh SabahiDepartment of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Mohsen KarimiDepartment of Biotechnology, Pasteur Institute of Iran, Tehran, Iran.
Hesam MirshahabiDepartment of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Tarbiat Modares University · IRMalek Ashtar University of Technology · IRPasteur Institute of Iran · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatitis delta virus (HDV) is a subviral human pathogen that exploits host RNA editing activity to produce two essential forms of the sole viral protein, hepatitis delta antigen (HDAg). Editing at the amber/W site of HDV antigenomic RNA leads to the production of the large form (L-HDAg), which is required for RNA packaging.

methodsIn this study, PCR-based site-directed mutagenesis by the overlap extension method was used to create the point mutation converting the small-HDAg (S-HDAg) stop codon to a tryptophan codon through three stages.

resultsSequencing confirmed the desirable mutation and integrity of the L-HDAg open reading frame. The amplicon was ligated into pcDNA3.1 and transfected to Huh7 and HEK 293 cell lines. Western blot analysis using enhanced chemiluminescence confirmed L-HDAg expression. The recombinant L-HDAg localized within the nuclei of cells as determined by immunofluorescence and confocal microscopy.

conclusionBecause L-HDAg requires extensive post-translational modifications, the recombinant protein expressed in a mammalian system might be fully functional and applicable as a tool in HDV molecular studies, as well as in future vaccine research.

Indexed as

Hepatitis Delta VirusL-HDAgSOEing-PCR

Identifiers

PMID26989717
PMCPMC4757064
OpenAlexW2267353159

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.